MedTrace Logo

Dose-dense ABVD First Line Therapy in Early Stage Unfavorable Hodgkin's Lymphoma

NCT02247869 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2018-02-09

No results posted yet for this study

Summary

Prospective, multicenter, Phase II trial designed to assess whether intensification of ABVD (dd-ABVD) is feasible and can improve the outcome of patients with early stage Hodgkin Lymphoma.

Conditions

Interventions

DRUG

dose dense ABVD

dose dense ABVD will be administered intravenously on day 1 and 8 every 21 days Chemotherapy regimen * Doxorubicin 25 mg/m2 i.v. day 1 and 8 * Bleomycin 10 mg/m2 i.v. day 1 and 8 * Vinblastine 6 mg/m2 i.v. day 1 and 8 * Dacarbazine 375 mg/m2 i.v. day 1 and 8 Granulocyte colony-stimulating factor (G-CSF): days 9 to 14

Sponsors & Collaborators

  • Fondazione Italiana Linfomi - ETS

    lead OTHER

Principal Investigators

  • Armando Santoro, M.D. · Humanitas Cancer Center - Department of Medical Oncology and Haematology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2015-06-30
Completion
2017-04-29

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02247869 on ClinicalTrials.gov